EMATRA is an oral retinoid derived from vitamin A used in haematologic oncology.
Mechanism of action:
Induces differentiation of abnormal promyelocytes into mature granulocytes
Inhibits the proliferation of leukaemic cells
Recommended for:
Patients with confirmed APL (M3 AML subtype)
As part of combination chemotherapy
Under oncologist supervision only
Acute promyelocytic leukaemia (APL, FAB classification M3)
Induction of remission
Used alongside cytotoxic agents
Tretinoin is administered orally according to a personalised regimen prescribed by a specialist. Dosage and duration depend on body weight, clinical status, and other medications in the treatment protocol. Strict medical monitoring is required.
Hypersensitivity to retinoids
Pregnancy and breastfeeding
Liver failure
Hypervitaminosis A
Concurrent use of tetracyclines (risk of increased intracranial pressure)
Retinoic acid syndrome (fever, oedema, respiratory issues)
Headache, nausea
Skin rash, dryness of skin and mucosa
Elevated liver enzymes
Hyperlipidaemia
Arrhythmias, thrombosis
Raised intracranial pressure
